Antimicrobial Resistance (AMR)
The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
OHE presented at the Global AMR R&D Hub Board of Members Meeting in Paris, on adapting HTA and payment mechanisms to incentivise new drugs to tackle…
Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance
7 October 2019
Research by OHE and the University of Sussex into patients’ preferences for diagnostic tests aimed at reducing antimicrobial resistance has been published in Applied Health Economics…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
A new OHE Research Paper summarises the findings of a project funded by the Wellcome Trust on innovative HTA methods and contracting for antibiotics. The paper…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel,…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’
An Insurance Framework for Funding New Antibiotics
22 September 2017
A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
1 October 2017
This briefing provides a detailed summary of a symposium held at the HTAi 2017 meeting in Rome. This briefing provides a detailed summary of a symposium…